Successful improvement of frequency and symptoms of premature complexes after oral magnesium administration.

Abstract

BACKGROUND:

Premature ventricular and supraventricular complexes (PVC and PsVC) are frequent and often symptomatic. The magnesium (Mg) ion plays a role in the physiology of cell membranes and cardiac rhythm.

OBJECTIVE:

We evaluated whether the administration of Mg Pidolate (MgP) in patients with PVC and PsVC is superior to placebo (P) in improving symptoms and arrhythmia frequency.

METHODS:

Randomized double-blind study with 60 consecutive symptomatic patients with more than 240 PVC or PsVC on 24-hour Holter monitoring who were selected to receive placebo (P) or MgP. To evaluate symptom improvement, a categorical and a specific questionnaire for symptoms related to PVC and PsVC was made. Improvement in premature complex density (PCD) per hour was considered significant if percentage reduction was >70% after treatment. The dose of MgP was 3.0 g/day for 30 days, equivalent to 260 mg of Mg element. Any patient had structural heart disease or renal failure.

RESULTS:

Of the 60 patients, 33 were female (55%). Ages ranged from 16 to 70 years old. In the MgP group, 76.6% of patients had a PCD reduction >70%, 10% of them >50% and only 13.4% <50%. In the P group, 40% showed slight improvement, <30%, in the PC frequency (p < 0.001). Symptom improvement was achieved in 93.3% of patients in the MgP group, compared with only 16.7% in the P group (p < 0.001).

CONCLUSION:

Oral Mg supplementation decreases PCD, resulting in symptom improvement.

• Authors: Cristina Nadja Muniz Lima De Falco, César Grupi, Eduardo Sosa, Maurício Scanavacca, Denise Hachul, Sissy Lara, Luciana Sacilotto, Cristiano F Pisani, José A F Ramires, Francisco Darrieux
• Journal: Arquivos brasileiros de cardiologia (Arq Bras Cardiol) Vol. 98 Issue 6 Pg. 480-7 (Jun 2012) ISSN: 1678-4170 [Electronic] Brazil
• PMID: 22584491 (Publication Type: Journal Article, Randomized Controlled Trial)

Chemical References

• Pyrrolidonecarboxylic Acid

Topics

• Adolescent
• Adult
• Aged
• Atrial Premature Complexes (drug therapy, prevention & control)
• Double-Blind Method
• Female
• Humans
• Male
• Middle Aged
• Placebo Effect
• Pyrrolidonecarboxylic Acid (administration & dosage)
• Statistics, Nonparametric
• Time Factors
• Treatment Outcome
• Ventricular Premature Complexes (drug therapy, prevention & control)
• Young Adult